Randomized trial · people
Melanotan I: more pain-free sun time in protoporphyria trials
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this rare light-sensitivity disease, afamelanotide implants were linked to more pain-free time in the sun and better quality of life than placebo, with mostly mild side effects.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2015
- Journal
- N Engl J Med
What they tested
The researchers tested whether afamelanotide implants could reduce pain and improve quality of life in people with erythropoietic protoporphyria, a severe skin condition in which sunlight triggers painful reactions.
How the study was done
Two multicenter, randomized, double-blind, placebo-controlled trials, one in the European Union (74 patients) and one in the United States (94 patients), gave either a 16 mg afamelanotide implant under the skin or a placebo (dummy) implant every 60 days. The main goal was the number of hours spent in direct sunlight without pain.

What they found
In the US study, median pain-free time in the sun after 6 months was 69.4 hours with afamelanotide vs 40.8 hours with placebo (P=0.04). In the European Union study, median pain-free time after 9 months was 6.0 hours vs 0.8 hours (P=0.005), and the afamelanotide group had fewer phototoxic reactions, which are painful reactions to light (77 vs 146, P=0.04). Quality of life improved with afamelanotide in both trials. Side effects were mostly mild, and the serious ones were not judged to be caused by the drug.
What it doesn’t show
Both trials enrolled only patients with erythropoietic protoporphyria, so they do not test other conditions or uses. They lasted 6 to 9 months, and they were funded in part by Clinuvel Pharmaceuticals.
The paper
Langendonk et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015.
The compound
More studies on Melanotan I
- Melanotan I plus UV-B: 48.64% vitiligo repigmentation at day 168Randomized trial · people · 2015
- Melanotan I: well tolerated in 6 acute stroke patientsClinical trial · people · 2023
- Melanotan II: erections in 17 of 20 men with erectile dysfunctionClinical trial · people · 2000
- Melanotan II: darker skin in 2 of 3 men in a small phase I trialClinical trial · people · 1996
- Melanotan II: melanoma diagnosed in a 20-year-old woman after useObservational study · people · 2014
- Every study on Melanotan I
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.